• Inspire Medical Systems has reported its full-year 2025 results, with sales rising to US$911.98 million and net income reaching US$145.42 million, driving basic earnings per share from continuing operations to US$4.95, up from US$1.80 a year earlier.
• The sharp improvement in profitability and earnings came after analysts had recently turned more cautious on near-term quarterly performance, highlighting a gap between expectations and how efficiently the business converted higher revenue into bottom-line growth.
• We’ll now examine how this strong full-year profit expansion, against previously cautious earnings expectations, reshapes Inspire Medical Systems’ investment narrative.

Outshine the giants: these 26 early-stage AI stocks could fund your retirement.

Inspire Medical Systems Investment Narrative Recap

To own Inspire Medical Systems, you need to believe its implantable sleep apnea therapy can justify continued investment despite execution and reimbursement risks. The latest 2025 results, with net income of US$145.42 million and EPS of US$4.95, suggest the company converted recent revenue growth into stronger profitability. That is helpful for the near term, but it does not remove the key risk around rollout execution, capacity constraints, and any future pressure on payer coverage.

The most relevant prior announcement is management’s January 2026 guidance, which pointed to full year 2026 revenue of US$1,003–1,013 million, following 2025 guidance of about US$911.8–912.0 million. That outlook was set before the strong full year 2025 earnings release and before analysts turned more cautious on near term EPS, so investors will be watching closely to see whether this guidance still looks realistic in light of execution risks and any evolving reimbursement trends.

But while the profit jump is encouraging, investors should also be aware of the risk that shifting reimbursement and payer cost pressures could...

Inspire Medical Systems' narrative projects $1.3 billion revenue and $103.6 million earnings by 2028.

Uncover how Inspire Medical Systems' forecasts yield a $124.40 fair value, a 82% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts were already cautious, assuming revenue of about US$1.2 billion and earnings of roughly US$65.6 million by 2028, so you may find their more pessimistic view on rollout and reimbursement risks a useful contrast to consensus forecasts as you weigh how this new earnings surprise might reshape expectations.

Explore 9 other fair value estimates on Inspire Medical Systems - why the stock might be worth just $71.17!

Build Your Own Inspire Medical Systems Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Inspire Medical Systems research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Inspire Medical Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Inspire Medical Systems' overall financial health at a glance.

Want Some Alternatives?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
• Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.